BioGAL is a market-driven developer of drug applications for cancer.
The Company has patented the work of Prof. Nechama Haran-Ghera from the Weizmann Institute of Science and Prof. Moshe Mittelman from the Tel-Aviv Sourasky Medical Center ( US and EU issued ) the use of Erythropoietin (EPO) against Multiple Myeloma (MM), an incurable hematological cancer of plasma cells.
BioGAL's observations are derived from initial clinical research and basic science research on murine animal models. Following clinical observation, the Company has carried out successful animal studies on various scientifically accepted myeloma models.
EPO-treated mice lived significantly longer than controls, suggesting that EPO has the ability to arrest or significantly slow down MM disease processes.